New drug could treat Alzheimer's, multiple sclerosis and brain injury

July 24, 2012

A new class of drug developed at Northwestern University Feinberg School of Medicine shows early promise of being a one-size-fits-all therapy for Alzheimer's disease, Parkinson's disease, multiple sclerosis and traumatic brain injury by reducing inflammation in the brain.

Northwestern has recently been issued patents to cover this new drug class and has licensed the commercial development to a that has recently completed the first human Phase 1 clinical trial for the drug.

The drugs in this class target a particular type of , which is a common denominator in these neurological diseases and in and stroke. This inflammation, also called neuroinflammation, is increasingly believed to play a major role in the progressive damage characteristic of these and brain injuries.

By addressing brain inflammation, the new class of drugs -- represented by MW151 and MW189 -- offers an entirely different to Alzheimer's than current ones being tested to prevent the development of beta in the brain. The plaques are an indicator of the disease but not a proven cause.

A new preclinical study published today in the Journal of Neuroscience, reports that when one of the new Northwestern drugs is given to a mouse genetically engineered to develop Alzheimer's, it prevents the development of the full-blown disease. The study, from Northwestern's Feinberg School and the University of Kentucky, identifies the optimal therapeutic time window for administering the drug, which is taken orally and easily crosses the blood-brain barrier.

"This could become part of a collection of drugs you could use to prevent the development of Alzheimer's," said D. Martin Watterson, a professor of and at the Feinberg School, whose lab developed the drug. He is a coauthor of the study.

In previous animal studies, the same drug reduced the neurological damage caused by closed-head traumatic and inhibited the development of a multiple sclerosis-like disease. In these diseases as well as in Alzheimer's, the studies show the therapy is critical.

MW151 and MW189 work by preventing the damaging overproduction of brain proteins called proinflammatory cytokines. Scientists now believe overproduction of these proteins contributes to the development of many degenerative as well as to the caused by traumatic brain injury and stroke.

When too many of the cytokines are produced, the synapses of the brain begin to misfire. Eventually the entire organization of the brain falls into disarray, like a computer failing. The neurons lose their connections with each other and can eventually die. The resulting damage in the cortex and hippocampus can compromise memory and decision-making.

"In Alzheimer's disease, many people now view the progression from mild cognitive impairment to full-blown Alzheimer's as an indication of malfunctioning synapses, the pathways that allow neurons to talk to each other," said Watterson, the John G. Searle Professor of Molecular Biology and Biochemistry. "And high levels of proinflammatory cytokines can contribute to synaptic malfunction."

Because this harmful inflammatory mechanism also appears to be a major player in other neurodegenerative disorders in addition to Alzheimer's, the class of drugs represented by MW151 might hold bright potential as co-therapies for Parkinson's disease, frontotemporal dementia, amyotrophic lateral sclerosis, M.S. and the longer term complications of brain injury, Watterson said.

"We need more studies of therapeutic time windows in models of these other diseases so we can better plan future clinical trials," Watterson noted.

In the new study by Northwestern's Watterson and Linda Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, a mouse model of Alzheimer's received MW151 three times a week starting at six months of age, right at the time the proinflammatory cytokines began to rise. This would be the comparable stage when a human patient would begin to experience mild cognitive impairment.

When the mice brains were later evaluated at 11 months (at a time when disease pathology is usually present), cytokine levels in the mice receiving the drug were restored to normal levels and their synapses were functioning normally. The inflammatory cytokine levels of the mice not receiving the drug, however, were still at abnormally high levels, and the mice had misfiring synapses.

"The drug protected against the damage associated with learning and memory impairment," Van Eldik noted. "Giving this drug before Alzheimer's memory changes are at a late stage may be a promising future approach to therapy."


In M.S., overproduction of the proinflammatory cytokines damage the central nervous system and the brain. The proteins directly or indirectly destroy the insulation or coverings of the nerve cells that transmit signals down the spinal cord. When the insulation is stripped, messages aren't properly conducted down the spinal cord.

When mice that were induced to develop an M.S.-like disease received MW151 orally, they did not develop disease as severe.

"We inhibited the development of the disease," said William Karpus, the Marie A. Fleming Research Professor of Pathology at the Feinberg School. "Now we need to learn if the drug can prevent relapses of M.S." That study is ongoing in mice and the results will determine whether a patient trial will be planned.

The only current oral drug treatment for M.S. acts at the level of the lymph nodes, Karpus said. Because the brain is the site of the inflammation and damage, a drug that works in the brain is an ideal therapy.


After a traumatic brain injury, the glia cells in the brain become hyperactive and release a continuous cascade of proinflammatory cytokines that -- in the long term -- can result in cognitive impairment and epilepsy. As a result of this hyperactivity, researchers believe the brain is more susceptible to serious damage following a second neurological injury.

In a study with mice, Mark Wainright, M.D., professor of pediatric neurology at Northwestern's Feinberg School and a physician at the Ann & Robert H. Lurie Children's Hospital of Chicago, showed that when MW151 is given during an early therapeutic window three to six hours after the injury, it blocks glial activation and prevents the flood of proinflammatory cytokines after a traumatic brain injury.

"If you took a drug like this early on after traumatic brain injury or a even a stroke, you could possibly prevent the long-term complications of that injury including the risk of seizures, cognitive impairment and, perhaps, mental health issues," Wainwright said.

Stroke also causes inflammation in the brain that may also be linked to long-term complications including epilepsy and cognitive deficits. As in traumatic brain injury, this inflammatory response is part of the recovery mechanisms used by the brain, so the use of brief and focused treatments like MW151 could prevent the harmful effects of inflammation while allowing the protective effects to occur unimpeded.

In another study, Wainwright showed MW151, when given after a traumatic brain injury, prevented the increased risk of epileptic seizures.

Explore further: Exercise may help prevent brain damage caused by Alzheimer's disease

Related Stories

Exercise may help prevent brain damage caused by Alzheimer's disease

August 15, 2011
Regular exercise could help prevent brain damage associated with neurodegenerative diseases like Alzheimer's, according to research published this month in Elsevier's journal Brain, Behavior, and Immunity.

Anti-inflammatory chemical could prevent stroke damage

December 5, 2011
(Medical Xpress) -- Drugs that block inflammation in the brain could help patients who have a stroke or a brain haemorrhage, Manchester scientists said today (5 December) at the British Society for Immunology Congress in ...

Traumatic brain injury linked with tenfold increase in stroke risk

July 28, 2011
If you suffer traumatic brain injury, your risk of having a stroke within three months may increase tenfold, according to a new study reported in Stroke: Journal of the American Heart Association.

Recommended for you

Neurons involved in learning, memory preservation less stable, more flexible than once thought

August 17, 2017
The human brain has a region of cells responsible for linking sensory cues to actions and behaviors and cataloging the link as a memory. Cells that form these links have been deemed highly stable and fixed.

Researchers make surprising discovery about how neurons talk to each other

August 17, 2017
Researchers at the University of Pittsburgh have uncovered the mechanism by which neurons keep up with the demands of repeatedly sending signals to other neurons. The new findings, made in fruit flies and mice, challenge ...

Researchers show how particular fear memories can be erased

August 17, 2017
Researchers at the University of California, Riverside have devised a method to selectively erase particular fear memories by weakening the connections between the nerve cells (neurons) involved in forming these memories.

How we recall the past: Neuroscientists discover a brain circuit dedicated to retrieving memories

August 17, 2017
When we have a new experience, the memory of that event is stored in a neural circuit that connects several parts of the hippocampus and other brain structures. Each cluster of neurons may store different aspects of the memory, ...

Study uncovers specialized mouse neurons that play a unique role in pain

August 17, 2017
Researchers from the National Institutes of Health have identified a class of sensory neurons (nerve cells that electrically send and receive messages between the body and brain) that can be activated by stimuli as precise ...

Scientists identify central neural circuit for itch sensation

August 17, 2017
Itching is an unpleasant sensation associated with the desire to scratch, and the itch sensation is an important protective mechanism for animals. However, chronic itch, often seen in patients with skin and liver diseases, ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jul 24, 2012
Wow! Effing amazing.
not rated yet Jul 25, 2012
methanol is an unexamined co-factor for brain diseases

WC Monte paradigm -- multiple sclerosis caused by methanol being made into formaldehyde inside cells of brain blood vessel walls by ADH1 enzyme, in humans only: Rich Murray 2012.07.25

Prof. Woodrow C. Monte, Food Science and Nutrition, Arizona State University, retired 2004:

textbook, and free articles, published journal paper, and 745 free online full text pdf medical research references, along with audio and video media:
19 video talks

Methanol (wood alcohol) has many sources:

aspartame, E951

smoke from wood, peat, cigarettes

fruits juices vegetables, especially tomatoes, preserved wet in cans, jars, plastics, at room temperature

many dark wines and liquors (fruit brandy is worst)

fermented, smoked, spoiled foods

fresh tomatoes, black currants

jellies, jams, and marmalades not made fresh and kept refrigerated

some coffees

chewing gum

bacteria in the colon
not rated yet Jul 28, 2012
I'm mjesfahani, http://en.wikiped...osis(MS)
read it and also be in touch with me please, your information about MS is good. I'm SP MSer.
not rated yet Jul 28, 2012
methanol/formaldehyde paradigm for multiple sclerosis, free full 56
page chapter 9 pdf, While Science Sleeps, 146 full text references
online, Prof. Woodrow C. Monte: Rich Murray 2012.03.20

list of 745 free full text pdf medical research references

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.